British Columbia’s recently-announced initiative to switch patients using biologic drugs to biosimilar equivalents has prompted “concerns” from patients and doctors, according to originator-backed lobbying group the Alliance for Safe Biologic Medicines.
ASBM – which counts among its member partners Amgen, Genentech and the US Biotechnology Innovation Organization brand industry association – labelled the BC government’s policy “an example of ‘non-medical switching’ – switching that results
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?